From: The impact of low-frequency, low-force cyclic stretching of human bronchi on airway responsiveness
 |  | Cyclic stretch effect on ΔEmax (ACh) difference between control and stretch group | Effect of pretreatment | Effect size pretreatment | |
---|---|---|---|---|---|
n | in absence of pretreatment (g) | in presence of pretreatment (g) | (g) | |d| [95% CI] | |
Epithelium removal | 13 | −0.01 ± 0.15 | 0.27 ± 0.14 | 0.27 ± 0.12a | 0.54 [−0.26–1.29] |
Indomethacin (1 μM) | 8 | 0.12 ± 0.25 | 0.19 ± 0.11 | 0.07 ± 0.25 | 0.25 [−0.75–1.22] |
MK476 (1 μM) | 7 | 0.15 ± 0.29 | 0.51 ± 0.23 | 0.37 ± 0.28 | 0.53 [−0.57–1.55] |
L-NAME (1 mM) | 14 | −0.01 ± 0.07 | 0.26 ± 0.14 | 0.25 ± 0.11a | 0.66 [−0.12–1.40] |
Nicardipine (10 μM) | 10 | 0.25 ± 0.18 | 1.02 ± 0.44b | 0.76 ± 0.43 | 0.73 [−0.21–1.60] |
Tetrodotoxin (1 μM) | 7 | 0.16 ± 0.25 | −0.02 ± 0.12 | −0.18 ± 0.30 | −0.35 [−1.38–0.73] |
Gadolinium (0.1 mM) | 8 | 0.11 ± 0.22 | 0.39 ± 0.19 | 0.28 ± 0.28 | 0.49 [−0.53–1.45] |
Tertiapine (10 μM) | 9 | −0.02 ± 0.08 | 0.25 ± 0.10b | 0.27 ± 0.18 | 0.95 [−0.03–1.92] |
Capsazepine (1 μM) | 8 | 0.36 ± 0.26 | 0.29 ± 0.19 | −0.07 ± 0.26 | −0.11 [−1.08–0.88] |
Calphostine C (0.1 μM) | 9 | 0.00 ± 0.28 | 0.18 ± 0.22 | 0.18 ± 0.22 | 0.24 [−0.70–1.15] |
SB203580 (0.1 μM) | 10 | −0.22 ± 0.21 | −0.25 ± 0.16 | −0.03 ± 0.25 | −0.05 [−0.93–0.83] |
Y27632 (1 μM) | 11 | −0.13 ± 0.22 | 0.21 ± 0.08b | 0.33 ± 0.21 | 0.63 [−0.25–1.46] |